Clinical Trial Update: PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a PD-1 antibody therapy in combination with infliximab for metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Infliximab (infliximab)
• PD-1 antibody therapy

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Metastatic Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING